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ABSTRACT: Tuberculosis (TB) can develop soon after antiretroviral treatment initiation, as the
result of restoration of the anti-TB specific immune response. This form of the disease is often
defined as ‘‘unmasked TB’’, and it represents a major challenge for severely immune-suppressed
HIV-infected subjects initiating treatment. Emergence of previously unrecognised TB disease
occurs frequently in countries where TB/HIV co-infection is common, and where antiretroviral
treatment has become increasingly accessible. The challenges posed by unmasked TB, such as
its high incidence, the lack of reliable diagnostic tools and the uncertainties on its optimal
management, may hamper our ability to face the TB/HIV epidemic. Therefore, unmasked TB
appears a major threat to global health and poses additional barriers to successful HIV/AIDS care
and treatment programmes.
This review focuses on the epidemiology, immunopathogenesis and clinical manifestations of
unmasked TB, and provides evidence-based recommendations for management and care of the
disease.
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T
uberculosis (TB) is the most common
opportunistic infection worldwide, and it
is a major contributor to the mortality of
people living with HIV/AIDS [1]. It is currently
estimated that over one million people worldwide
have TB/HIV co-infection and the burden of the
diseases is particularly high in sub-Saharan Africa.
The risk of developing active TB is greatly
increased in HIV-infected compared with HIV-
negative subjects [2]. Although combination anti-
retroviral therapy (cART) reduces this risk, TB
incidence among treated HIV-infected patients
remains higher than that among HIV-negative
subjects in the same community [3, 4].
The rapid expansion of antiretroviral roll-out
programmes in high TB burden areas, mainly
in southern Africa, has been associated with an
unexpectedly high occurrence of TB during the
first 3 months of cART, suggesting a potential role
of cART-driven immune restoration in ‘‘unmask-
ing’’ subclinical TB [3]. The underlying mechan-
isms through which TB is unmasked have yet to be
fully explained. A growing body of indirect evid-
ence suggests that the phenomenon is the result of a
complex interaction between cART-driven immune
restoration and Mycobacterium antigen load. The
resulting disease spectrum may range from typical
TB presentations to TB presenting as an exagger-
ated inflammatory response due to dysregulated
immune restoration, commonly referred to as
immune reconstitution inflammatory syndrome
(IRIS) [5].
The clinical management of this peculiar manifes-
tation of TB/HIV co-infection can be particularly
challenging, due to the difficulties in its diagnosis
and the uncertainties regarding its optimal man-
agement. Therefore, unmasked TB appears a major
threat to global health and poses additional barriers
to successful HIV/AIDS care and treatment pro-
grammes. Notwithstanding, to our knowledge, no
recent review has addressed these topics in major
journals.
AIM
Aim of the present perspective article is to highlight
the burden of TB unmasked by cART in HIV/TB
epidemics and its individual and public health
implications, either in low- or high-income settings.
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We discuss the available evidence on the different aspects of
unmasked TB, starting from the definitions proposed, then
analysing the incidence of TB soon after cART initiation, risk
factors and mortality, immunopathogenesis, clinical features,
prevention and treatment.
METHODS
The present article is based on a comprehensive review of peer-
reviewed studies published on TB unmasked by cART. Literature
searches of the PubMed/MEDLINE databases were undertaken
to identify pertinent articles. The searches were first performed in
September 2009 and then repeated in September 2010 and May
2011, in order to update the reference list. The following search
string was used to identify articles focusing on or mentioning
unmasked TB: (HIV OR AIDS) AND (TUBERCULOSIS OR TB)
AND (UNMASK* OR IRIS OR ‘‘IMMUNE RECONSTITUTION’’).
A second, wider search was conducted in order to identify all
studies on TB occurring during antiretroviral treatment. The
following search string was used: (HIV OR AIDS) AND
(TUBERCULOSIS OR TB) AND (HAART OR ARV OR
ANTIRETROVIRAL). All searches were limited to English
language. In addition, the websites of the major international
congresses on HIV were browsed in order to identify relevant
unpublished studies. Conference abstracts more than 1 yr old
were discarded, if full data were still unpublished.
The articles were then independently sifted by two authors (G.
Lapadula and A. Bandera), based on abstract and, if deemed to
be necessary, by reading the full paper. Articles judged to be
irrelevant by both authors were discarded, while disagreements
were resolved through discussion. Eventually, the reference lists
of the selected articles were browsed to identify further papers of
interest.
Each article was then categorised by its relevance to one or more
of the following subtopics: 1) definition of unmasked TB; 2)
incidence, risk factors and mortality of TB during cART; 3)
immunopathogenesis; 4) clinical presentation; 5) prevention and
treatment.
Overview of the different definitions of unmasked TB
Due to lack of diagnostic tests, diagnosis of unmasked TB relies
solely on case definition. However, that definition is not stand-
ardised, and varies from study to study. Table 1 shows the defini-
tions proposed to date.
During an expert meeting held in Kampala (Uganda) in 2006, a
provisional case definition was proposed by the International
Network for the Study of HIV-associated IRIS (INSHI) [6]. The
authors define any new presentation of TB occurring within the
first 3 months of cART as ‘‘cART-associated TB’’, while the term
‘‘unmasking TB-IRIS’’ is reserved for a subset of cART-associated
TB whose clinical course is either characterised by heightened
intensity or has been complicated by a paradoxical reaction.
‘‘Unmasking TB-IRIS’’ is distinguished from TB-IRIS (in the
paper termed ‘‘paradoxical tuberculosis-associated IRIS’’), defined
as a paradoxical reaction and/or a deterioration of an already
diagnosed TB, which occurs after the start of cART in a patient
receiving anti-TB treatment.
The foremost advantage of this definition is its clinical validity,
which has been documented. In a prospective cohort of 498 HIV-
infected adults initiating cART in South Africa, the INSHI
definition was, in fact, in good agreement with the opinion of
an expert panel [10]. Nonetheless, the definition failed to identify
about one-third of the cases that had been classified as unmasked
TB by the experts. The main reasons for the discrepancy were
delayed presentation (more than 3 months after cART initiation),
or absence of a ‘‘heightened intensity of clinical manifestation’’ in
cases where, according to expert opinion, immune reconstitution
TABLE 1 Unmasked tuberculosis (TB) definitions
Study Definition
MEINTJES et al. [6] Unmasking TB-associated IRIS
1) Patient is not receiving treatment
for TB when cART is initiated
AND
2) Active TB within 3 months of
cART initiation
AND
3) Either one of the following:
a) Heightened intensity of clinical manifestations,
particularly if there is evidence of a marked
inflammatory component to the presentation
OR
b) Once established on TB treatment, a clinical
course that is complicated by a paradoxical reaction
MANABE et al. [7] Unmasked TB
1) Latent TB before the development of HIV-induced
immunosuppression
AND
2) TB occurring as a consequence of the
up-regulation of memory immune response during
immune reconstitution induced by cART
LAWN et al. [8] Unmasking TB
TB presenting during the initial months of immune
recovery (‘‘ART-associated TB’’) whereby immune
recovery triggers the presentation of TB
HADDOW et al. [9] Unmasking IRIS
Clinical criteria
1) Temporal relationship: cART initiation must
precede clinical deterioration
2) New onset of symptoms of an infectious or
inflammatory condition after initiation of cART
3) Consistent with the presence of pre-existing
causative pathogen or antigen at the time of
starting cART
4) Either of the following
a) Onset within 3 months of initiating cART
b) Atypical or exaggerated clinical, histological
or radiological findings
Exclusion of other causes
Event not explained by
1) Expected clinical course of another condition
2) Drug toxicity
3) Newly acquired infection
Failure of ART treatment
IRIS: immune reconstitution inflammatory syndrome; (c)ART: (combination)
antiretroviral treatment.
G. LAPADULA ET AL. PERSPECTIVE: UNMASKED TUBERCULOSIS
c
EUROPEAN RESPIRATORY JOURNAL VOLUME 39 NUMBER 5 1065
had played an important role in the clinical presentation of
the disease. Criteria regarding the clinical characteristics of the
disease can indeed be quite subjective, due to the wide spectrum
of TB manifestations. For this reason, clinical differentiation
between incident TB and TB elicited by cART remains difficult in
practice.
Other authors refer to ‘‘unmasked TB’’ as a wide spectrum of
TB clinical presentations, triggered by cART-induced immune
recovery [5]. In a recent review, MANABE et al. [7] proposed a new
way of classifying the different forms of TB occurring during
cART. According to the authors, ‘‘primary TB’’ is only temporally
associated with cART and is not associated with a rapid recall of
TB antigen-specific memory immune response. Conversely,
‘‘unmasked TB’’ occurs in the subset of patients who develop
clinically recognisable TB after the initiation of cART because
of the restoration of TB antigen-specific functional immune
responses. Among them, only a proportion of individuals
develops an exaggerated inflammatory response, defined as
‘‘unmasked TB-IRIS’’. The authors speculate that these three
clinical presentations are part of a disease spectrum in which
interaction between the TB antigen burden and degree of immune
restoration determines the magnitude of clinical symptoms.
Similarly, LAWN et al. [8] used the term ‘‘unmasking’’ TB in
reference to subclinical TB that is present but unrecognised before
treatment initiation and whose early onset after cART introduc-
tion is determined by the restoration of TB-specific immune
response. Both definitions, while theoretically intriguing and
biologically plausible, are limited by the absence of objective
criteria able to distinguish between pre-existing subclinical
TB and incident TB that occurs early during cART as a result
of persistent immune deficiency. The practical utility of such
distinction in the clinical practice is, anyhow, questionable.
HADDOW et al. [9] recently proposed a new general definition of
‘‘unmasking IRIS’’. Its application to TB may resolve some of the
problems with previous definitions, by classifying most of the
events occurring soon after cART introduction as unmasked TB.
According to the authors, the diagnosis of unmasked TB can be
made when a strict temporal correlation exists between anti-
retroviral treatment and TB (i.e. TB presentation within 3 months
of initiating cART), even in settings of typical disease progression.
Conversely, an atypical or exaggerated course could be con-
sidered to be consistent with unmasked TB, even in cases
presenting more than 3 months after cART initiation (table 1).
This comprehensive definition is likely to prove more sensitive
than the INSHI definition, but will probably lack in specificity in
settings where TB is highly prevalent. Further evaluation in
clinical practice is, therefore, required.
As available clinical and immunological markers are as yet
unable to differentiate pre-existing from incident TB, a margin of
uncertainty and arbitrariness is unavoidable in any definition.
Meanwhile, current data support the adoption of the INSHI
definition in research practice.
Incidence of TB and unmasked TB during cART
Several observational studies have been conducted to assess the
burden of TB among individuals receiving cART [3, 4, 8, 11–32].
Estimates of TB incidence, however, differ greatly among the
published studies. Differences in TB case definitions, length
of follow-up, degree of immune suppression prior to cART
initiation or rate of TB infection in the studied populations
are all plausible explanations for the apparent discrepancies.
Nonetheless, all the studies consistently report that TB incidence
is higher early in the course of cART than at later time points
during treatment and, in many cases, more than half of TB cases
occurring during cART are diagnosed within the first 3 months
of treatment [11, 13, 23–25, 29, 30, 32]. LAWN et al. [8] observed that
the risk of TB occurrence during the first months of cART, among
patients with a CD4+ T-cell counts ,200 cells per mL, was 40%
(95% CI 6–61%) higher than among those with the same CD4+ T-
cell counts during long-term treatment. The authors suggested
that this excess rate of TB is directly attributable to the ‘‘unvei-
ling’’ effect of cART-induced immune restoration. Consistent
with this hypothesis, TB rates were reported to remain high soon
after cART initiation and, in some cohorts, were even higher than
pre-cART rates. In an observational cohort study conducted in
the USA, incidence of TB during the first 6 months of cART was
almost double than that in persons not on cART (0.4 versus 0.21
per 100 person-yrs of follow-up), although the difference was not
statistically significant adjusting for CD4+ T-cell count [17].
Similarly, in a South African cohort, TB incidence before and
within 3 months of cART was 10.5 and 13 per 100 person-yrs of
follow-up, respectively [32].
Table 2 shows the incidence of TB occurring during cART and
shortly after cART initiation in various studies, conducted both
in high- and low-income settings.
The introduction of cART has dramatically reduced TB
incidence among the resident HIV-infected population of
high-income countries. The incidence of TB in the Swiss cohort
decreased from 0.78 per 100 person-years before cART to 0.22
per 100 person-yrs during cART. In this study, the incidence
during the first trimester was similar to pre-cART levels,
whereas it significantly decreased from month 3 onwards [11].
Two large collaborative cohort studies, conducted in Europe
and North America, consistently demonstrated that 0.9–1% of
patients beginning cART develop TB during treatment over an
extended follow-up and that incidence of unmasked TB during
the first months of treatment is three to four times higher than
incidence of TB during later time-points (1.3–1.7 per 100
person-yrs in the first trimester, compared with 0.3–0.62 per
100 person-yrs after month 6) [14, 15]. This means that, in
settings with low prevalence of TB in the general population
and high (and early) accessibility of antiretroviral drugs, a
significant proportion of TB cases is, in fact, seen in patients
receiving cART, with most of these cases occurring soon after
cART introduction (up to 15% of all cases of TB in HIV-infected
individuals in a British case series) [13].
In studies conducted in low-income countries, 3–14% of HIV-
infected patients developed TB during cART (table 2). In these
cohorts, the estimated incidence of unmasked TB was 10- to 40-
fold higher than in high-income settings, ranging from 5.6 per
100 patient-yrs [20] to 22.1 per 100 patient-yrs of follow-up [22].
In other words, while in high-income countries approximately
one out of every 300 to 1,000 patients is diagnosed with TB
within 3 months of starting cART, the proportion of patients
diagnosed with unmasked TB in low-income countries ranged
from a minimum of one case per 80 patients in a South African
cohort [3] to a maximum of one case per 11 patients in a
Cambodian cohort [23], meaning that unmasked TB, while a
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clinical and diagnostic challenge worldwide, is a particularly
heavy burden in resource-constrained settings.
Risk factors for unmasked TB upon receipt of antiretroviral
treatment
Two factors contribute primarily to the risk of unmasked TB
disease after cART initiation: frequency of TB infection in the
asymptomatic HIV-infected population and degree of immune
suppression before cART.
In a study comparing TB incidence in five different low-income
countries, risk of unmasked TB was higher in countries with
higher TB burden, such as Senegal and Malawi, than in countries
where overall TB incidence was lower, such as Cameroon [23]. In
high-income countries, low rates of unmasked TB largely reflect
the lower incidence of TB, either in the general population or
among HIV-infected subjects, compared with resource-limited
countries. Notably, HIV-infected immigrants from countries with
high TB incidence may run risks of unmasked TB comparable
those run in their country of origin. For instance, in a case-
series of 267 individuals who immigrated into the UK from
Sub-Saharan Africa, eight (3%) patients developed TB within
3 months of cART [13]. Similarly, Sub-Saharan country of origin
and being foreign born were demonstrated to be risk factors for
unmasking TB-IRIS in a French case–control study and in a US
observational cohort study, respectively [16, 17].
The predictive value of baseline CD4+ T-cell count has been
convincingly demonstrated in several studies: the lower the
CD4+ T-cell count before cART, the higher the risk of TB during
cART [3, 8, 14, 15, 17, 27–29, 32]. LAWN et al. [8] estimated that
the risk of unmasked TB among patients who had a CD4+
T-cell count ,200 cells per mm3 and ,100 cells per mm3 was
approximately three and four times higher than among those
with o200 CD4+ per mm3, respectively. CD4+ T-cell counts also
contribute to the high incidence of unmasked TB recorded in low-
income countries, where treatment is generally initiated in the
lowest CD4+ strata. One study also suggested that unmasking-TB
IRIS is associated with steeper CD4% increases, and more rapid
HIV-RNA decline subsequent to cART introduction, compared to
non-IRIS-like cART-associated TB [16].
In developing countries, other factors have been independently
associated with increased risk of TB during cART. Most of them,
such as low body mass index (BMI), anaemia, World Health
Organization stage and weight for age, may themselves be
indirect measurements of immune suppression and disease
advancement, independent of CD4+ count [3, 4, 22, 23, 26, 30].
Moreover, low BMI and recent weight loss may also reflect
undiagnosed TB before treatment initiation [30].
Past history of TB has been linked to risk of recurrence upon
cART initiation in two studies conducted in Abidjan (Ivory Coast)
and in one conducted in South Africa [20, 24, 32]. However, this
association has not been confirmed by other studies and, by
contrast, LAWN et al. [3] suggested that past treatment for TB,
particularly if recently completed, may exert a protective effect
against risk of active TB after cART initiation. Given the possible
implications in terms of secondary prophylaxis, further studies
are needed in order to clarify whether a previous episode of TB
poses patients at additional risk of TB disease during cART.
Unmasked TB and risk of death
Unmasked TB is an important cause of mortality and has been
associated with a high risk of death. When assessed, the mortality
of the patients diagnosed with unmasked TB exceeded 25% [4, 22,
29]. While the occurrence of TB following initiation of cART has
been consistently associated with significant higher mortality
compared with TB-free patients [4, 22], it is unclear whether the
occurrence of unmasked TB early during the course of cART
may put patients at additional risk of death, compared with
TB occurring at later time-points. In one study, the subjects
diagnosed with TB within the first 3 months of cART did not
experience an excess mortality risk compared with subjects who
were diagnosed with TB later [4]. Conversely, in a study
conducted in Haiti, patients who received a diagnosis of TB
during the first 3 months of cART were three times more likely to
die than other patients with AIDS and TB [29]. As the authors
recognised, in this study, delayed diagnosis and treatment of
TB already present at baseline (almost 50% of patients were
symptomatic at the time that cART was started) is likely to have
greatly contributed to the high mortality. Moreover, despite an
attempt to correct for baseline CD4+ T-cell strata, the deepest
immune suppression of patients with unmasked TB may also
have influenced their prognosis. Although it cannot be ruled out
that exaggerated response due to unmasking-TB IRIS may also
have contributed to high mortality, the overall contribution of TB-
IRIS events to TB mortality is generally low [25, 33].
Anyway, irrespective of its causes, unmasked TB has been
associated with high risk of death and, therefore, represents an
important burden in low-income countries, leading to a sub-
stantial increase of avoidable mortality in antiretroviral roll-out
programmes.
Immunopathogenesis of unmasked TB
Following initiation of antiretroviral treatment, restoration of
CD4+ T-cells is documented to occur and is associated with
augmentation of bactericidal effector function (cytotoxicity and
macrophage-activating cytokine production) with respect to
the pre-antiretroviral treatment phase [34]. This is reflected in
the restoration of a delayed type hypersensitivity reaction to
mycobacterial antigens administered intradermally to HIV-
infected patients [35, 36]. Several studies have demonstrated that
recovery of a protein purified derivative (PPD)-specific response
is specific for immune reconstitution with cART [37–40].
Tuberculin-specific T-cells are known to recover rapidly, both
qualitatively and quantitatively, within 3–6 months of cART
initiation and successful HIV control. Among HIV/TB co-
infected patients, these cells have been shown to reach propor-
tions of up to 33% of the peripheral CD4+ T-cells after 9 months
of cART and to have an effector memory CD45RA-CD62L+
phenotype. Moreover, a recent study showed that HIV-infected
patients with low CD4+ T-cell counts (,200 per mL) had a
significantly higher proportion of interferon (IFN)-c+ cells after
PPD stimulation than either patients with high CD4+ T-cell
counts (.500 per mL) or HIV-negative controls. However,
analysis of interleukin (IL)-2 and tumour necrosis factor-a
production in response to TB antigens, alongside IFN-c, showed
that patients with high CD4+ T-counts had significantly more T-
cells co-expressing more than one cytokine than patients with low
CD4+ T-cell counts, indicating that a polyfunctional CD4+ T-cell
profile could be protective against TB in HIV-infection [41].
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TABLE 2 Studies reporting incidence and risk factors for tuberculosis (TB) during antiretroviral treatment
Location Study Population
characteristics
Patients on
cART n
Incidence
rates of TB
during cART
Incidence
rates of TB within
3 months of cART
Early/any
TB
CD4+
before
cART
Factors associated
with TB during cART
High-income
countries
Switzerland LEDERGERBER
et al. [11]
HIV+ starting
PI-containing cART
2410 6 (0.2%) (0.22 per
100 person-yrs)
3 (0.1%) (,0.5 per
100 person-yrs)
50% Median 188
per mL
Italy GIRARDI et al. [12] HIV+ starting cART 387 1 (0.2%) 0
UK BREEN et al. [13] HIV/TB during
cART
19 16 84% Median 112
per mL
UK BREEN et al. [13] Sub-Saharan
Africans starting
cART
267 11 (4.1%) 8 (3%) 73%
Europe and
North America
GIRARDI et al. [14] Asymptomatic
HIV+ starting cART
17142 173 (1%) (0.46 per
100 person-yrs)
55 (0.3%) (1.3 per
100 person-yrs)
32% 55% ,200
per mL
cART duration, calendar
year, CD4+ nadir, risk factor
for HIV (IVDU, heterosexuality)
Europe and
North America
BRINKHOF et al. [15] HIV+ starting cART
observed over 1 yr
22217 205 (0.9%) (1 per
100 person-yrs)
1.7 per 100
person-yrs
Median 234
per mL
CD4+ nadir, risk factor for
HIV (heterosexuality)
France VALIN et al. [16] HIV+ starting cART 11 unmasking
TB-IRIS
Median 116
per mL
Sub-Saharan African,
baseline HIV-RNA, CD4%
increase, HIV-RNA decline
USA PETTIT et al. [17] HIV+ starting cART 3492 17 (0.5%) (0.13 per
100 person-yrs)
7 (0.2%) (0.4 per
100 person-yrs
within 6 months of
cART)
41% Median 242
per mL
Male sex, black ethnicity,
place of birth (foreign born),
risk factor for HIV
(heterosexuality), CD4+
nadir, baseline HIV-RNA
Low-income
countries
Thailand SUNGKANUPARPH
et al. [18]
AIDS patients
starting cART
60 8 (13.3%) Median 9
per mL
Uganda JOHN et al. [19] HIV/TB during
cART
131 29 22%
Ivory Coast SEYLER et al. [20] HIV+ starting cART 129 12 (9.3%) (4.8 per
100 person-yrs)
3 (2.3%) 25% Median 129
per mL
Previous TB diagnosis
South Africa LAWN et al. [3] HIV+ starting cART 346 27 (7.8%) (2.4 per
100 person-yrs)
4 (1.2%) (3.35 per
100 person-yrs
within 1 yr of cART)
15% Median 242
per mL
Age, CD4+ nadir,
WHO stage
Uganda BAALWA et al. [21] HIV+ without TB
starting cART
271 26 (9.6%) 8 (2.8%) 31%
South Africa LAWN et al. [22] HIV+ without TB
starting cART
756 81 (10.7%) (10.5
per 100 person-yrs)
40 (5.3%) (22.1 per
100 person-yrs)
49% Median 96
per mL
Current CD4+
Cambodia BONNET et al. [23] HIV+ starting cART 717 100 (13.9%) (7.6,
12.7 per 100
person-yrs)#
63 (8.8%) 63% 66% ,50
per mL
Thailand BONNET et al. [23] HIV+ starting cART 500 57 (11.4%) (10.4,
4.3 per 100
person-yrs)#
30 (6%) 53% 72% ,50
per mL
Kenya BONNET et al. [23] HIV+ starting cART 654 73 (11.2%) (17.6,
6.9 per 100
person-yrs)#
41 (6.3%) 56% 36% ,50
per mL
Malawi BONNET et al. [23] HIV+ starting cART 1064 80 (7.5%) (14.3,
2.1 per 100
person-yrs)#
50 (4.7%) 62% 21% ,50
per mL
Cameroon BONNET et al. [23] HIV+ starting cART 216 10 (4.6%) (4.8, 0 per
100 person-yrs)#
8 (3.7%) 80% 25% ,50
per mL
Africa, Asia and
South America
BRINKHOF et al. [15] HIV+ starting cART 4540 258 (5.7%) (7.4 per
100 person-yrs)
10.7 per 100
person-yrs
Median 107
per mL
CD4+ nadir, sex, age
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Taken together, these findings suggest that the relatively sudden
and rapid restoration of functional CD4+ T-cells specific for
Mycobacterium tuberculosis may be massively involved in the
pathophysiology of unmasked TB disease after cART initiation.
Observations that unmasked TB disease is more common among
formerly naı¨ve patients with very low CD4+ cell counts (,200
cells per mL) and with strong response to cART support this
hypothesis [16].
Expansion of tuberculin-specific T-cells has also been cited as a
possible cause of IRIS, a complex phenomenon which likely
shares a common immunological pathway with unmasked TB.
Amplification of IFN-c producing T-cells has been reported
among patients with TB-IRIS and has been associated with an
acute burst of other T-helper type 1 (Th1) and pro-inflammatory
cytokines/chemokines, which provokes conditions favouring
deregulated immune activation [42]. Similarly, rapid increases in
IFN-c responses to RD1 antigens and to PPD have been found
among patients with unmasked TB, suggesting that unmasked
TB and TB-IRIS are both associated with restoration of immune
response against M. tuberculosis antigens [43]. However,
increases in IFN-c responses during TB-IRIS were shown to be
relatively slow, compared with unmasked TB, hinting that
additional immune defects may play important roles in TB-IRIS.
Dysregulation of IFN-c activity, manifested by higher levels of
IL-18 (an inducer of IFN-c production) and CXCL10 (a marker of
IFN-c production), has indeed been demonstrated during TB-
IRIS, but not during unmasked TB [44]. Moreover, circulating IL-
10 has been reported to be lower during TB-IRIS events than
during non-IRIS events, whereas no differences in IL-10 levels
were found between unmasked TB and control events [45]. IL-10
is produced by monocytes and T-regulatory (T-reg) cells and
down-regulates many immune functions, including Th1 cyto-
kines and killing of mycobacteria. A defect in T-reg function and
a reduction in its ability to downregulate immune response are
likely to be among the mechanisms underlying the exaggerated
inflammatory response observed during TB-IRIS [46]. In
contrast, the role of the T-reg subset would appear to be less
important in determining unmasked TB, which is apparently
driven by a restoration of effector T-cell responses, in the absence
Location Study Population
characteristics
Patients on
cART n
Incidence
rates of TB
during cART
Incidence
rates of TB within
3 months of cART
Early/any
TB
CD4+
before
cART
Factors associated
with TB during cART
Uganda MOORE et al. [4] HIV+ without TB
starting cART
969 53 (5.5%) (3.9 per
100 person-yrs)
23 (2.4%) (7.5 per
100 person-yrs
within 6 months
of cART)
43% Median 127
per mL
Low BMI
Ivory Coast MOH et al. [24] HIV+ without TB
starting cART
792 23 (2.9%) (3.3 per
100 person-yrs)
5.6 per 100
person-yrs
,50% Median 252
per mL
Previous TB diagnosis,
haemoglobin, current
CD4+
South Africa MURDOCH et al. [25] HIV+ without TB
starting cART
338 16 (4.7%) 11 (3.2%) 69% Median 115
per mL
Ethiopia HURUY et al. [26] HIV+ without TB
starting cART
178 20 (11.2%) Mean 123
per mL
Senegal ETARD et al. [27] HIV+ without TB
starting cART
352 42 (11.9%) (2.3 per
100 person-yrs)
4.5 per 100
person-yrs within
1 yr of cART
Median 128
per mL
Haemoglobin, CD4+ nadir
South Africa SMITH et al. [28] Children ,2 yrs of
age starting cART
169 12 (7.1%) 11 (6.5%) 92% 39% ,15
CD4%
Age ,6 months, CD4%,
HIV-RNA, weight for age
Haiti KOENIG et al. [29] HIV/TB during
cART
97 49 50.5% CD4+
Malawi BEDELL et al. [30] HIV+ without TB
starting cART
2281 67 (2.9%) Weight loss .10%,
WHO clinical stage 4
South Africa LAWN et al. [8] HIV+ without TB
starting cART
1032 171 (16.6%) (7.3
per 100 person-yrs)
18.8 per 100
person-yrs
Median 97
per mL
Current CD4+
Burkina Faso DEMBELE´ et al. [31] HIV+ starting cART 2383 70 (2.9%) 33 (1.4%) (5.77 per
100 person-yrs)
47.1% Mean 128
per mL
Low BMI, CD4+ nadir
South Africa NICHOLAS et al. [32] HIV+ without TB
starting cART
19325 933 (4.8%) (5.4
per 100 person-yrs)
470 (2.4%) (13 per
100 person-yrs)
50.4% Median 142
per mL
Urban sites, male sex,
calendar year, low BMI,
previous TB diagnosis,
CD4+ nadir
cART: combination antiretroviral treatment; PI: protease inhibitor; IVDU: intravenous drug user; IRIS: immune reconstitution inflammatory syndrome; WHO: World Health
Organization; BMI: body mass index. Note that data may not directly reflect those reported in the cited papers, because patients with a diagnosis of TB before cART initiation
have been excluded from the table. Data for incidence rates are given for the first 3 months of antiretroviral treatment, unless otherwise specified. #: incidence rates for
pulmonary and extrapulmonary TB, respectively.
TABLE 2 Continued
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of proper dysregulation between the effector and the regulatory
functions of immune response [45].
Further studies, however, are needed to clarify the role of T-reg
cells in the pathogenesis of TB IRIS and unmasked TB. It is likely
that exploration of the frequency and the function of these cells,
not only in the peripheral blood, but also in the site of disease,
could elucidate their exact function.
Figure 1 summarises the hypothetical immunopathogenesis of
unmasked TB manifesting with and without IRIS.
Clinical features of unmasked TB
Unmasked TB can vary widely in the degree of its clinical
presentation, and there is no clear evidence that unmasked TB is
clinically distinguishable from other HIV-associated TB or that
unmasking TB has different features from paradoxical TB-IRIS.
Restoration of immune function following cART introduction
can simply elicit or exacerbate symptoms of TB, or it can be
responsible for exaggerated inflammatory response, similar to
TB-IRIS. Table 3 shows the clinical features of unmasked TB cases
as reported in published cohort studies, case series and case
reports.
Data from larger cohorts show that roughly two-thirds of
unmasked TB cases present with lung involvement as primitive
and exclusive localisation [22, 23, 31, 32]. This contrasts to some
extent with data from cohorts of untreated patients with
advanced HIV infection, among whom extrapulmonary involve-
ment accounts for 50% of cases or more [59, 60]. Of note, the high
rate of pulmonary TB observed in the first trimester of cART has
been associated in particular with a higher incidence of sputum
smear-negative forms, as compared with TB occurring later
during cART [31, 32]. This observation, although potentially
influenced by diagnostic capacities, deserves attention, because it
can delay diagnosis and treatment of unmasked TB.
Similar diagnostic problems are posed by extrapulmonary TB,
which accounted for 30 to 40% of all unmasked TB, in various
cohorts. The most common areas of extrapulmonary localisation
of unmasked TB are lymphatic, gastrointestinal and central
nervous system [16, 21, 33, 47, 51, 52]. Other, less frequent,
manifestations include glaucomatous hepatitis, genito-urinary
TB, splenic abscesses and hypercalcaemia. Unusual and extre-
mely severe presentation of unmasked TB have been reported,
encompassing adult respiratory distress syndrome [48], bronch-
iolitis obliterans organising pneumonia [55], pyomiositis [57],
multiple cerebral tuberculomas [52] and haemophagocytic
syndrome [58]. These manifestations are likely to be due to
an IRIS-like inflammatory reaction, as a consequence of cART-
induced restoration of specific TB immune response.
Prevention of unmasked TB
Given the high disease burden and mortality of HIV-infected
subjects diagnosed with unmasked TB, all possible efforts should
be made to prevent it, particularly in developing countries. In
the present paper, we will use the term ‘‘primary prevention’’ to
indicate interventions aimed at reducing the risk of TB among
HIV-infected patients initiating cART. Those interventions aimed
at identifying patients at risk of unmasked TB and/or at
increasing the yield of early unmasked TB diagnosis will be
referred to as ‘‘secondary prevention’’.
Two different, and possibly complementary, strategies are prime
candidates for primary prevention: early cART introduction and
preventive treatment with isoniazid.
As previously mentioned, unmasked TB is strictly dependent on
CD4+ T-cell count: the lower the count, the higher the risk. Timely
cART is therefore a potent intervention for unmasked TB
prevention, provided that it is initiated before significant immune
depletion. The exact risk reduction associated with different
CD4+ T-cell strata, however, is yet to be determined. While it has
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FIGURE 1. Postulated immunopathogenesis of a) unmasking tuberculosis
(TB)-immune reconstitution inflammatory syndrome (IRIS) and b) unmasked TB
without IRIS. Both conditions are associated with restoration of immune response
against Mycobacterium tuberculosis antigens due to antiretroviral treatment.
Unmasking TB-IRIS (a) is characterised by slow increases in interferon (IFN)-c
responses, dysregulation of IFN-c activity, increasing levels of interleukin (IL)-18
and CXCL10 and defect in T-regulatory (T-reg) cell function, leading to exaggerated
inflammatory response. Tissue recruitment of dendritic cells and increase in
peripheral cd T-cells contribute to IRIS manifestations. Unmasked TB with no IRIS
manifestation (b) is associated with a more rapid IFN-c increase in absence of T-reg
functional defects. TNF: tumour necrosis factor. Adapted from the Wikimedia
Commons files "Image:Macrophage.png" and ‘‘Image: Dendritic cell.png’’ available
from http://commons.wikimedia.org/wiki.
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been convincingly demonstrated that the elevation of the CD4+
threshold for cART eligibility from 200 to 350 cells per mL (or
even more) significantly reduces TB among patients awaiting
cART [61], indirect evidence suggests that the benefit of this shift
in terms of prevention of unmasking TB is likely to be low. In fact,
LAWN et al. [8] showed that, among patients with CD4+ T-cell
counts .200 per mm3, TB incidence rates during early cART
were comparable to rates during long-term treatment. This
suggests that, under these circumstances, the role of immune
recovery in unmasking subclinical TB is less important.
Therefore, in terms of unmasked TB prevention, promoting early
HIV diagnosis and minimising health system delays in cART
initiation are likely to be more cost-effective than further antici-
pating cART debut among patients already on longitudinal care.
Isoniazid preventive treatment (IPT) is a second strategy that
could be effective in reducing the risk of developing active TB
and, subsequently, unmasked TB upon cART initiation.
Integration of IPT programmes in HIV care has been demon-
strated to be both feasible and practical, and IPT used
concomitantly with cART among the common scenario of
patients with advanced HIV infection is likely to have great
benefit in terms of preventing unmasked TB. A recent study
offered new insights about the benefits of concomitant IPT and
cART treatment. Among previously cART-naı¨ve patients with
symptomatic disease and/or low CD4+ T-cell counts, a sig-
nificantly lower mortality rate was observed among those
receiving IPT together with cART, compared with those receiving
cART alone [62]. Whether this effect is driven, at least in part, by a
reduced incidence of unmasked TB is unknown and further
study is needed to specifically address the impact of concurrent
IPT and cART on unmasked TB among formerly naı¨ve patients
with advanced HIV disease.
The identification of the patients who are more likely to develop
unmasked TB after cART initiation is a mainstay of secondary
prevention. Nonspecific markers of inflammation, such as D-
dimer [63], C-reactive protein and plasma IFN-c [64], have been
demonstrated to be higher before cART initiation among those
who subsequently develop unmasked TB. Their utility as
diagnostic markers is, however, very limited. ELLIOTT et al. [43]
proposed that IFN-c release assays prior to cART might help in
predicting unmasked TB and in stratifying patients in low- and
high-risk groups. Nonetheless, IFN-c release assays are generally
unable to distinguish between active disease and latent infection.
Moreover, the need for advanced infrastructure means these tests
are of little or no use in resource-constrained settings. A more
interesting marker is lipoarabinomannan (LAM), a major
component of M. tuberculosis cell wall, which can be detected in
the urine of TB patients, using a relatively easy and inexpensive
procedure. Urine LAM assay was demonstrated to be specific
and substantially more sensitive than sputum microscopy as a
routine diagnostic TB screening test among patients with CD4+
T-cell counts ,100 cells per mL [65].
Treatment of unmasked TB
Most unmasked TB has a clinical presentation similar to that of
incident TB. Since therapy for susceptible TB is typically as
effective in the HIV-infected patient as it is in the general
population, prompt initiation of appropriate chemotherapeutic
regimen is the only effective therapeutic measure available.
Treatment of unmasked TB must be integrated with close follow-
up and with immediate revision of cART, in order to minimise
adverse interactions between anti-tubercular and antiretroviral
drugs, keeping in mind that the use of rifamycins is essential, and
that rifabutin is an acceptable alternative to rifampin if this choice
is required by drug interaction issues. The response to treatment
of unmasked TB is comparable to that of other TB/HIV co-
infections, as demonstrated by the low rate of recurrence after TB
treatment [32].
Occasionally, unmasked TB can present with a marked inflam-
matory component and/or with a clinical course complicated
by paradoxical reactions. Management of unmasked TB with
a paradoxical presentation has not been extensively studied.
However, since the underlying immunopathogenetic mechanism
is likely to be similar to that of TB-IRIS, the therapeutic approach
is similar. Published cases and clinical experience suggest that
continuation of cART is reasonable in the majority of cases.
Paradoxical reactions are self-limiting in most patients, and
treatment is usually reserved for severe manifestations, such as
life-threatening conditions or in patients at risk of permanent
sequelae. Discontinuation of cART should be considered only as
a last resort, given the higher mortality rate of patients with HIV/
TB not receiving concomitant antiretroviral treatment [66, 67].
Only in cases ‘‘resistant’’ to corticosteroids should cART
interruption be considered [68].
In general, symptomatic agents, such as corticosteroids or non-
steroidal anti-inflammatory drugs, are effective in obtaining
symptom relief and in controlling inflammatory response.
Corticosteroid treatment, although widely used, has yet to be
standardised, and published studies and case series report
varying choices of dosing and treatment duration. Severe IRIS-
like reactions can be managed with prednisone at a starting
dosage of 1 to 2 mg?kg-1?day-1. In cases with central nervous sys-
tem involvement, dexamethasone use (8 mg twice daily) could be
preferred. Steroids were also demonstrated to be safe and
effective when used in not life-threatening TB-IRIS. In a recent
randomised placebo controlled trial, a 4-week course of predni-
sone reduced hospitalisation and hastened the improvement in
signs and symptoms associated with TB-IRIS [69]. The risk of
adverse reactions attributable to corticosteroids, however, should
be carefully evaluated before initiating therapy, because more
side-effects were reported in the prednisone than in the placebo
arm, although the difference did not reach statistical significance.
Occasionally, corticosteroid treatment has been reported to be
ineffective in controlling severe cases of TB-IRIS. Where maximal
dosages of corticosteroids fail to control a life-threatening
inflammatory reaction, alternative drugs can be considered as
salvage treatment. Leukotriene antagonists, such as montelukast
and zafirlukast, have been considered in a few reports as
treatment for IRIS [70].
CONCLUSIONS
All these challenges make unmasked TB a dangerous threat in
antiretroviral roll-out and TB control programmes, particularly
in resource-limited countries, and limit global and national
capacities to curb the HIV/TB epidemic. Delays in diagnosis
and treatment and, in some cases, exaggerated inflammatory
response, are causes of a high attributable mortality and put other
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TABLE 3 Clinical features of published cohort studies, case series and case reports of unmasked tuberculosis (TB)
Study Location Cases Symptoms before cART
initiation
Clinical features Sputum smear/culture
SHELBURNE et al. [47] USA 1 Not reported Fever, weight loss, abdominal pain
due to bowel (cecal) TB
Culture-positive
GOLDSACK et al. [48] UK 1 Asymptomatic; normal
chest radiograph
Fever, night sweats, shortness of breath rapidly
evolving in respiratory failure due to ARDS
Smear- and culture-positive
JOHN et al. [19] Uganda 1 Malaise, weight loss,
low-grade fever, intermittent
cough; normal chest radiograph
Fever, dry cough, miliary pulmonary infiltrates Smear- and culture-negative
SEYLER et al. [20] Sub-Saharan
Africa
3 Not reported 1 pulmonary, 2 disseminated 2 smear-positive,
culture-positive
BREEN et al. [13] England 13 60% symptomatic (5 fever,
4 weight loss, 2 cough,
2 night sweats)
38% pulmonary, 24% extrapulmonary,
38% miliary, 61% ‘‘paradoxical reactions’’
85% culture-positive
MILLER et al. [49] UK 1 Weight loss, minimal productive
cough, fever
Pulmonary TB Smear- and
culture-negative
BONNET et al. [23] Cambodia,
Thailand, Kenya,
Malawi,
Cameroon
192 Not reported 68% pulmonary, 32% extrapulmonary Not reported
LAWN et al. [22] Sub-Saharan
Africa
40 Not reported 78% pulmonary, 22% extrapulmonary 41% smear-positive,
81% culture-positive
ZAMPOLI et al. [50] South Africa 7 children Not reported 6 pulmonary TB, 1 disseminate TB
(pulmonary+lymphoadenitis+meningitis)
4/6 smear- and culture-positive
(1 MDR), 1/6 smear-negative
and culture-positive, 2/6
smear- and culture-negative
PARK et al. [51] South Korea 5 Not reported 3 pulmonary, 2 extrapulmonary (1 cerebral);
lymphadenitis in 3/5 cases
Not reported
MOH et al. [24] Ivory Coast 23 Not reported 64% pulmonary, 24% extrapulmonary,
12% disseminated
Not reported
DAUTREMER et al. [52] France 1 Not reported Tuberculous meningitis (acute onset),
multiple cerebral tuberculomas
Culture-positive CSF
TUON et al. [53] Brazil 1 Not reported Hepatosplenic abscesses and
granulomatous hepatitis
Culture of liver
biopsy negative
MEINTJES et al. [6] Not reported 1 Low-grade fever,
retrosternal chest pain,
dry cough; normal
chest radiograph
Fever and respiratory distress due to
pulmonary TB
Smear-positive
OCAMA et al. [54] Uganda 7 Not reported Suspected TB hepatitis Not reported
BAALWA et al. [21] Uganda 8 Not reported 1 pulmonary, 7 extrapulmonary (2 meningitis,
1 lymphadenitis, 1 abdominal), 3 disseminated
1 smear-positive
MURDOCH et al. [25] South Africa 18 Not reported 50% pulmonary, 25% extrapulmonary,
25% disseminated
69% smear- or
culture-positive
LAWN et al. [55] South Africa 1 Asymptomatic Bronchiolitis obliterans organising
pneumonia, death
Smear- negative
LAWN et al. [8] South Africa 203 Not reported 74% pulmonary, 26% extrapulmonary Not reported
MANABE et al. [7] USA 1 Chronic watery diarrhoea,
subjective fevers, chills,
weight loss; normal chest
radiograph; PPD negative
Fever and cough due to upper
lobe cavitary TB
Smear-negative,
culture-positive
CASTELNUOVO et al. [33] Uganda 2 Asymptomatic 1 extrapulmonary TB, 1 TB meningitis Not reported
TSAO et al. [56] Taiwan 1 Weight loss Hypercalcaemia, splenic abscess Not reported
CHEN et al. [57] Taiwan 1 Weight loss Gluteal pyomiositis Not reported
SORIA et al. [58] Italy 1 Not reported Haemophagocytic syndrome due to
disseminated TB
Smear- and
culture-negative
VALIN et al. [16] France 11 Not reported 4 pulmonary, 3 extrapulmonary,
4 disseminated (2 CNS involvement)
All culture-confirmed
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HIV-infected patients at risk of TB nosocomial transmission.
Given the high disease burden, it is crucial to invest all possible
efforts to prevent unmasked TB among patients starting
antiretroviral treatment, either by impeding TB disease or by
increasing the yield of subclinical TB diagnosis before treatment
initiation. The problem deserves urgent attention by researchers
and political commitment in order to adopt evidence-based pre-
emptive policies. Research priorities include the identification of
new rapid, affordable and reliable diagnostic tools. Moreover,
further investigation on the optimal timing and duration of
IPT, as well as implementation of IPT in HIV/AIDS national
programmes, are urgently needed. Prompt anti-TB treatment and
management of paradoxical inflammatory reactions are the
cornerstones of unmasked TB treatment.
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